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Abstract
Background: Silicone implants are biomaterials that are frequently used in the medical industry due to their
physiological inertness and low toxicity. However, capsular contracture remains a concern in long-term transplantation.
To date, several studies have been conducted to overcome this problem. This review summarizes and explores
these trends.
Main body: First, we examined the overall foreign body response from initial inflammation to fibrosis capsule
formation in detail and introduced various studies to overcome capsular contracture. Secondly, we introduced
that the main research approaches are to inhibit fibrosis with anti-inflammatory drugs or antibiotics, to control the
topography of the surface of silicone implants, and to administer plasma treatment. Each study examined aspects of
the various mechanisms by which capsular contracture could occur, and addressed the effects of inhibiting fibrosis.
Conclusion: This review introduces various silicone surface modification methods to date and examines their limitations.
This review will help identify new directions in inhibiting the fibrosis of silicone implants.
Keywords: Fibrosis, Inflammation, Silicone implant, Foreign body reaction, Capsular contracture, Modification
Introduction
Silicone is the most common material used in medical
devices that are inserted into the human body due to its
physiological inertness, low toxicity, and antiadhesive
properties. In particular, silicone implants are used in
plastic surgery for breast augmentation and breast
reconstruction [1]. According to the Plastic Surgery
Statistics Report of 2017, 300,378 breast augmentation
operations were performed—a 3% increase from 2016.
Silicone implant surgeries are the most common type of
cosmetic surgery cases. However, this surgery is often
accompanied by capsular contracture (CC) with an inci-
dence of approximately 10.6% [2, 3]. CC results from the
immune response to a foreign body, causing pain and
discomfort and resulting in the distortion of both the
implant and the patient’s chest [4]. CC has long been
studied; however, the precise mechanism by which it
occurs has not yet been clarified. Bacterial contamin-
ation and the foreign body reaction (FBR) are known to
be the main causes.
Implants are being improved to overcome these prob-
lems. The first improvement involves reducing bacterial
contamination of the implant, and the second involves
modifications to minimize the FBR. Whereas second-
generation implants focused on functional and aesthetic
improvements, in third- and fourth-generation implants,
the shell was modified to reduce leakage of the gel filling
agent and to increase the cohesion of the gel itself
[5–10]. Through these improvements, an anatomical
model was produced. When fifth-generation implants
emerged, the CC incidence was reduced, and rupture of
the silicone implants decreased. The safety of the implants
also improved [8, 10]. The current sixth-generation im-
plants focus on surface modifications that minimize the
FBR. However, varying degrees of CC are still reported,
depending on the topography of these surfaces [11, 12].
Previous studies have shown that more malignant CC
occurs in smooth implants than in textured implants. A
microtextured implant represents a compromise between
smooth and textured implants.
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In this review, we introduce silicone implant modifica-
tion methods to reduce bacterial contamination and the
FBR. In addition to physical surface modifications, we
also introduce various chemical surface modifications of
silicone implants currently under study.
Mechanism of fibrosis
Fibrosis is a complicated process which is initiated by
various reactions in vivo and progresses due to different
reactions of various cellular factors. The most common
fibrosis reaction is the FBR, which occurs when biomate-
rials are implanted. Fibrosis is an in vivo defense mech-
anism caused by infection, autoimmune factors, foreign
material insertion, spontaneous factors, and cancer [13].
It occurs through a chain reaction of various factors—
most frequently through a reaction with a foreign body—
and its frequency has gradually increased with the increas-
ing number of breast augmentation surgeries that intro-
duce diverse biomaterials into the body [14, 15].
In this review, we focus on the occurrence of fibrosis
via the implantation of biomaterials. The fibrotic re-
sponse to biomaterials is caused by an immune reaction,
and the overall 6-step reaction occurs through adaptive
immune reaction over a certain period. Cellular activity
is altered depending on the duration of the immune re-
action, and the final effect of fibrosis occurs via changes
in the expression pattern of the involved factors [16, 17].
The stages of fibrosis are as follows: 1. blood-biomaterial
interaction, 2. provisional matrix formation, 3. acute in-
flammation, 4. chronic inflammation, 5. foreign body giant
cell formation, and 6. fibrous capsule formation [4, 18].
Blood-biomaterial interaction
The blood-biomaterial interaction is initialized by the
leakage of blood at the wound site when an implant is
inserted and results in the surface bonding of proteins in
the blood. This protein surface adsorption differs de-
pending on the surface characteristics of the implant
[19]. In general, adsorption of the proteins in the blood
occurs first, and subsequent binding of additional pro-
teins occurs due to the presence of cells at the implant-
ation site. The proteins thus induce cellular activity
through the binding of cells present in vivo [20]. This
step plays a major role in inhibiting the surface exposure
of primary implants through the accumulation of pro-
teins on the surface of the foreign material, which causes
cellular activation through surface-adsorbed proteins. A
protein layer with a thickness of 2–5 nm is formed on
the surface of the biomaterials, which induces the forma-
tion of a provisional matrix through cellular activation
and the additional adsorption of proteins [18, 21]. This
effect is called the Vroman effect [22, 23]. At the begin-
ning of this step, the albumin present in the blood accu-
mulates on the surface, and over time, it is replaced by
high-affinity proteins, such as fibrinogen, kininogen, fi-
bronectin, and vitronectin.
Provisional matrix formation
In the provisional matrix formation step, high-affinity pro-
teins (i.e., fibrinogen, kininogen, fibronectin, and vitronec-
tin) combine to form a provisional matrix [24, 25]. The
fibrinogen present in the matrix is replaced with fibrin
over time, although some fibrinogen remains for platelet
binding and the cellular activity that occurs during the
next phase [22, 26]. Additionally, the matrix formed dur-
ing this step adsorbs various factors through the residual
fibrinogen and thereby contains factors that activate cells,
such as macrophages, during the next stage [20]. In this
step, preparations for cellular activation and activity fac-
tors (von Willebrand factor) present in the blood are cap-
tured in the provisional matrix via alpha integrin. Based
on this information, preparations for the progression of
inflammation can be considered [4].
Acute inflammation
Acute inflammation is an early stage of the cellular reac-
tion during the development of fibrosis and is caused by
multiple reactions of various inflammatory cells (i.e.,
neutrophils, eosinophils, basophils and others) [27, 28].
Acute inflammation occurs in a short time, ranging from
a few hours to a few days, and is linked to chronic in-
flammation that occurs at the end of acute inflamma-
tion. Neutrophils and eosinophils (polymorphonuclear
cells; PMNs) play a major role in this early inflammatory
reaction and activate cells through the expression of
various factors (i.e., TNF-α, interleukin family, IFN-γ)
[27, 29]. Neutrophils induce inflammation through the
secretion of several cytokines and induce fibrosis
through the release of matrix metalloproteinases (MMPs),
elastase and cathepsin [30]. Mast cells and PMN-derived
cellular factors present at this step are also known to play
a major role in fibrosis [31]. Histamine, IL-4, and IL-13
expressed by mast cells, as well as IL-8, monocyte chemo-
attractant protein-1 (MCP-1), and macrophage inflamma-
tory protein-1ß (MIP1ß), increase the recruitment of
leukocytes and the number of macrophages. Thus, acute
inflammation progresses through a fibrotic reaction and
leads to chronic inflammation [27].
Chronic inflammation
Chronic inflammation occurs for 2–3 weeks, during
which the cytokines and cells for fibrosis are recruited
and activated. Lymphocyte and monocyte infiltration
primarily occur, and throughout these phenomena, cells
remain close to the biomaterials and secrete IL-4, IL-13,
and other factors [32, 33]. These secreted factors affect
macrophage activity and cause fusion into foreign body
giant cells (FBGCs). In chronic inflammation, cytokines
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that induce collagen synthesis in the periphery of bioma-
terials are primarily expressed, rather than platelet-de-
rived growth factor (PDGF), vascular endothelial growth
factor (VEGF), or transforming growth factor beta
(TGF- β) [34–36]. The MCP and MIP cytokine families
are also expressed. During this period, macrophages play
a major role. They are recruited by various factors and
are expressed and activated during the fibrotic reaction.
In chronic inflammation, granulation tissue forms
around the biomaterials through the activity of the fac-
tors and cells described above [30, 37].
Foreign body reaction
The FBR step is the stage during which the FBGCs
formed during chronic inflammation generate fibrosis. It
is also the step during which cells that play a major role
in the synthesis of collagen, such as fibroblasts, myofi-
broblasts, and FBGCs, are activated. FBGCs are formed
by the fusion of macrophages that are activated via spe-
cific cytokines, and when the implant is present, this for-
mation is maintained for a longer period. These FBGCs
remove foreign substances in vivo through phagocytosis
and cause cell activation. FBGCs express CD11, CD45,
and CD31 proteins as well as other receptors capable of
binding to IL-1, IL-2, IL-4, and IL-8 on their surface
membranes [4, 38]. Notably, the expression patterns of
macrophages in vivo are distinct (M1 and M2 macro-
phages), and the expression patterns of various cytokines
vary according to the phenotype of each macrophage.
IL-10, TGF-β, and MCP-1 are expressed in the early
phase of the FBR, as are IL-1α, IL-6, IL8 and TNF-α,
which are proinflammatory cytokines [39, 40]. The ex-
pression of these factors modulates the activity of mac-
rophages and FBGCs, determines the presence or
absence of fibrosis at the capsule formation stage, and
regulates fibrosis severity by changing the activity of the
factors according to the characteristics of the biomate-
rials [38].
Fibrous capsule formation
Finally, the fibrous capsule is formed through the several
preceding steps, and fibrosis is terminated. In this step,
collagen is synthesized in the peripheral region to isolate
foreign materials in vivo, thereby stabilizing the
biological reaction by reducing the stimulation of all bio-
logical reactions. At this stage, factors typically expressed
by M2 macrophages play a major role in controlling col-
lagen synthesis [39]. PDGF, VEGF, and TGF-β are typical
factors that induce collagen synthesis and ECM remod-
eling by stimulating keratinocytes, fibroblasts, endothe-
lial cells, thrombocytes, and adipocytes, which play a
major role in collagen synthesis [31, 41]. Initially, colla-
gen type III is synthesized to form a coarse matrix; over
time, this matrix stabilizes and replaces collagen type I,
resulting in complete isolation [42]. After this step, the
in vivo reaction is stabilized, and the immune response
by foreign materials in vivo is also stabilized. However, if
isolation is not properly performed at this step, more se-
vere fibrosis, such as scarring and CC, will occur.
Surface modification
Modification of surface topography
Smooth surface
The earliest form of silicone breast implant had a
smooth surface and was made commercially available
with little knowledge of the in vivo immune response.
These smooth silicone implants continue to be used to
the present day but are still reported to cause severe fi-
brosis. According to previous studies, smooth implants
cause a reduced inflammatory reaction in in vivo implant-
ation as well as reduced physical stimulation [43, 44].
Although smooth implants have been used consistently as
implantable devices for breast reconstruction because of
these advantages, their frequency of use is decreasing be-
cause the incidence of CC is greater with the use of
smooth implants than other surface types. Furthermore,
because of the inability to fix the smooth silicone breast
implant by generating seroma in vivo [45], smooth silicone
breast implants are no longer recommended [46, 47].
However, despite the drawbacks of smooth silicone breast
implants, they are still being used due to their ability to
create a perfect circular breast shape.
Textured surface
Implants with a textured surface represent an improve-
ment over smooth-surfaced silicone breast implants: tex-
tured implants with a surface roughness of 100–300 μm
avoid fibrosis. Textured implants have been developed
through three generations of implant designs and con-
tinue to improve fibrosis inhibition as information about
in vivo fibrosis is acquired [48]. In textured silicone
breast implants, the capsule tissue of the collagen is con-
structed during in vivo implantation, which facilitates
the fixing of the implant position in vivo. Because of this
advantage, textured silicone breast implants are cur-
rently used in breast reconstruction surgery and are con-
tinuously being developed because they can be formed
into various shapes by facile in vivo fixation.
Droplet-shaped implants are available on the market
today only with a textured surfaces. Textured silicone
breast implants are known to cause less fibrosis in vivo,
and the frequency of CC relative to smooth implants is
5–10% less [43]. Textured silicone breast implants are
frequently used for various drug-loaded implants, which
are being developed as the next generation of implants
due to the ease of drug loading on the surface and
sustained drug release from the surface in vivo. From
this perspective, the development of functional silicone
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breast implants with various fibrosis-inhibiting drugs
(tranilast, zafirlukast, montelukast, etc.) has been re-
ported [49–51]. A recent study, however, has reported a
strong association between these implants and anaplastic
large cell lymphoma (ALCL), and they are therefore be-
ing replaced by the next generation of implants [52].
Micro/Nanotextured surface
Implants with micro- or nanotextured surfaces have
been developed as next-generation implants. By control-
ling the roughness of the existing textured surface on
the micro- or nanoscale, implants with characteristics of
both smooth and textured surfaces can be developed
[53]. Based on studies of commercial products, fibrosis
occurs less frequently in the in vivo implantation of
these latest implants. In general, micro- and nanotextur-
ing of the surface of silicone breast implants produces a
surface roughness of 10 to 100 μm, and fibrosis in vivo is
reduced due to the surface topography of textured sili-
cone breast implants. Additionally, the frequency of CC
will eventually decrease with decreased of inflamma-
tion in the early inflammation phase compared to
that in smooth-surfaced silicone breast implants.
However, since micro and nanotextured surface im-
plants have only recently been developed, clinical data
are not sufficient and the stability of implant fixation
remains uncertain.
Antiadhesive modification
To avoid the FBR, silicone implant materials may be
treated to obtain antiadhesion properties. There are
some reports of CC suppression when such methods are
used [54–57]. For example, a study by Park et al. investi-
gated Guardix-SG, a biodegradable membrane that acts
as an antiadhesion barrier [56]. Other conventional anti-
adhesion agents are composed of highly viscous compo-
nents, and their physical properties are fixed. However,
Guardix-SG, which is composed of alginate and poloxa-
mer, changes its physical properties in gel form when
the temperature rises. In a similar case, a study by Lew
et al. showed that in rats, capsule thickness was signifi-
cantly decreased in the experimental group compared to
the control group when antiadhesion barrier solution
(AABS) was used [57]. In this paper, hyaluronic acid
(HA) was used as an AABS, and there was a reduction
of approximately 53% in the capsule thickness compared
to that of the saline-treated group. In the rat in vivo ex-
periment, the AABS volume was equal to the volume of
the implant, but a different volume could be expected to
be effective in a clinical trial. If AABS is tested in clinical
trials, the optimal concentration to cover the implant to
inhibit CC will be found.
Antibacterial modification
Several papers have shown that CC occurs due to bac-
terial presence as well as an FBR to silicone, and also
confirmed that bacterial colonization is closely related to
high-grade capsular contracture [58, 59]. For examples,
In the patients who experienced CC, the presence of
bacteria was confirmed by isolating the strains through
vortexing and sonication after implant removal surgery.
Furthermore, the serum hyaluronan level of the patient
showed a statistically significant increase, with a high
Baker grade in CC patients [58, 60]. Additionally, por-
cine in vivo studies that involve the inoculation of a hu-
man strain of Staphylococcus epidermidis on silicone
implants show that the presence of bacteria has a signifi-
cant impact on CC [61]. The exact mechanism by which
the presence of biofilm affects CC is unknown, but re-
search has shown that the incidence of CC can be low-
ered by using antibiotics and povidone-iodine irrigation
to eliminate bacteria [62, 63]. In addition to these surgi-
cal treatments, several studies have reported that the
introduction of antibacterial properties into the implant
itself may lower the incidence of CC.
Plasma-assisted surface modification
Plasma is defined as an ionized gas that has the same
amount of negatively and positively charged ions. Plasma
treatment was proven to be a highly effective sterilization
measure against Escherichia coli, Staphylococcus strains,
Pseudomonas aeruginosa and Bacillus strains in several
studies [64]. In contrast to autoclave sterilization, plasma
sterilization has the advantage that the properties of the
material can be preserved at high temperature and high
pressure [65]. Additionally, because the residue after
sterilization is nontoxic, the nonionized original gas does
not pose any safety risks to researchers and users. Oxygen
(O2) is the most commonly used gas. O, OH and OOH
are created when oxygen is in a plasma state. OH is
known to have the highest sterilizing power, and its steril-
izing efficiency increases with O2 concentration [64, 66].
Modification of the hydrophilic surface by plasma treatment
Silicone breast implants are hydrophobic. Therefore,
there is a material limitation that the implant itself cannot
contain the hydrophilic antibiotic and povidone-iodine.
However, when plasma treatment is performed, OH
groups are present on the surface, and the silicone surface
becomes hydrophilic. In the work of Barnea Y, et al., each
group was irrigated after the plasma treatment or no treat-
ment, and the sterilization efficiency was substantially im-
proved in the plasma-treated implants [62, 67].
Silicone shells with the ability to absorb water after
plasma treatment exhibit prolonged antibacterial proper-
ties. In the case of non-plasma-treated silicone implants,
fluorescence microscopy showed that the surface of the
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shell disc was covered with a layer of P. aeruginosa.
Treatment with gentamicin removed a small number of
bacteria, and the surface was slightly improved. How-
ever, in the plasma-treated group, complete eradication
of the bacterial layer was observed.
Direct treatment with antibiotics
The inoculation of smooth silicone implants with S.
epidermidis extracted from actual CC patients resulted
in a spherical formation with a high Baker grade; how-
ever, the incidence of CC significantly decreased when
patients were treated with an antibiotic-impregnated
mesh [61]. In addition, in a study by Jacombs A, et al.,
SEM analysis of an implant removed 16 weeks after
transplantation demonstrated that the antibiotic-treated
group formed less biofilm.
This finding suggests that the inhibition of bacterial
adhesion during breast implant insertion can be used as
a strategy to inhibit biofilm formation. The antibiotic-
impregnated mesh showed a considerable influence on
the Baker grade. In addition, the tonometry data showed
that the antibiotic-impregnated mesh had a large surface
area. This finding implies that even smaller volumes of
silicone implants can be as safe and effective as existing
implants [61].
Surface modification using antifibrosis drugs
Triamcinolone
Steroids are widely used to promote anti-inflammatory
activity. Glucocorticoids are known to inhibit inflamma-
tory cytokines, such as TNF-α and IL--1β, at the gene
level [68–70]. In addition to direct action, the downregu-
lation of chemoattractants and adhesion molecules that
promote the invasion of inflammatory cells also leads to
overall anti-inflammatory effects [71]. In addition, ex-
posure to this drug can be expected to inhibit direct or
indirect fibrosis by blocking the inflow of PMNs and
monocytes and reducing TGF-β production. The im-
plant was coated to perform sustained release of the
drug and thus to effectively suppress fibrosis and CC
around the silicone implant. Triamcinolone is an
FDA-approved drug that is usually not continuously ad-
ministered but instead is often administered via a local
shot. However, in the case of glucocorticoids, continuous
exposure may cause various side effects. Typical symp-
toms are skin thinning and muscle loss. Therefore, it is
very important to treat the patient with the correct dose.
Notably, these side effects were observed in the experi-
mental group at a high concentration, but there were no
side effects within the therapeutic window; rather, de-
creased collagen density and the inhibition of various
fibrosis-related cytokines were observed [72]. Inflamma-
tion levels due to the FBR were also significantly lower
than those in the controls, especially for early inflammation.
Notably, the amount used in the in vivo model was
approximately 2000-fold lower than the dose applied
in clinical practice, and this low concentration proved
to be sufficient for local sustained delivery [72]. How-
ever, adverse effects remain an issue.
Tranilast
When selecting a drug, it is very important to select the
pathway intended to block fibrosis. Tranilast is a drug
that targets TGF-β by directly blocking the secretion of
TGF-ß and inhibiting the expression of its receptor. This
effect inhibits the phosphorylation of the Smad pathway,
directly or indirectly blocking TGF-β family signaling
[73–75]. Tranilast is mainly used to treat asthma, keloid
scars, and hypertrophic scars, but it is not used to sup-
press CC. However, its ability to inhibit fibroblast and
collagen production was observed and applied to sili-
cone implants.
Experiments on its efficacy in an in vivo rat model
showed a noticeable decrease in capsule thickness and
collagen density in drug-treated implants 12 weeks after
transplantation. Although the drug was released steadily,
most of the drug was released during the first 5 days.
However, TGF-ß expression was still decreased after 4
weeks. These results suggest that inhibition of capsule
formation by inhibiting macrophage and fibroblast infil-
tration into the silicone implant site can be inhibited
only by early TGF-beta inhibition [50].
Montelukast and zafirlukast
Montelukast and zafirlukast are drugs used in clinical
practice as inhibitors of cysteinyl leukotrienes (CysLTs)
[76–78]. When silicone implants are implanted and
chronic inflammation occurs, CysLTs cause the migra-
tion of fibroblasts to the surface of the implants and
promote fibroblast differentiation into myofibroblasts.
When fibroblasts become myofibroblasts, alpha smooth
muscle actin (α-SMA) expression increases with collagen
production, and the ability to contract [79–81] is
strengthened, which leads to CC. Montelukast is a drug
that is known to inhibit CysLT production [82, 83]. It is
a specific leukotriene receptor antagonist that specific-
ally inhibits the production of leukotriene D4 (LTD4).
Montelukast is known to bind to the type 1 CysLT re-
ceptor (CysLT1) present in the cell membrane of PMNs
[82–84]. It is also suitable for breast implants because of
its ability to reduce fibroblasts and myofibroblasts and
to inhibit collagen production.
When montelukast was coated on the implants, the
production of CysLTs and the number of fibroblasts de-
creased, as expected, in the in vivo rat model, and this
effect was confirmed to be stronger when the drug was
delivered for a longer period with poly(lactic-co-glycolic
acid) (PLGA). This finding confirms that the inhibition
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of TGF-β expression and the number of myofibroblasts
can be reduced by inhibiting CysLT production alone.
However, macrophages were not effectively reduced,
likely because CysLT receptors were more abundant in
fibroblasts than in macrophages [85].
Likewise, zafirlukast is also a leukotriene receptor an-
tagonist used orally to treat asthma. Similarly, the ability
to inhibit eosinophilic recruiting and inhibit the ability
of smooth muscle can be expected to inhibit fibrosis
when applied to CC [86]. The work of A. Spano et al.
showed effective suppression of capsule formation on both
sides of the silicone disk. The inflammatory response
control group was surrounded by granulocytes and a large
number of eosinophils, while the inflammatory response
was also lower in the drug treatment group [49].
Halofuginone
Halofuginone is a substance that interferes with Smad3
phosphorylation in the TGF-β signaling pathway in a
manner similar to that of tranilast. Halofuginone has
been used as an inhibitor of various types of fibrosis by
inhibiting collagen I production [87–89]. However, be-
cause the systemic use of drugs can have many side ef-
fects, it may be beneficial to apply them to medical
Fig. 1 Overview of different PDMS breast implant surface modifications. a SEM images and scheme of PDMS breast implants with smooth, microtextured,
and textured surface morphology. The scale bar is 100 μm. The schematic depicts (b) antibacterial mesh, (c) antiadhesion barrier solution (AABS), (d) oxygen
plasma modification to change hydrophobicity to hydrophilicity, and (e) antifibrosis drugs coated on the PDMS breast implant surface
Shin et al. Biomaterials Research           (2018) 22:37 Page 6 of 9
devices that can be delivered locally, such as silicone im-
plants. Therefore, the main purpose of the study by
McGaha et al. was to determine whether coating an im-
plant with halofuginone could inhibit CC from forming
at the foreign body [90]. No side effects were found
when the drug was delivered to the local site. After 3
months, it was confirmed that in the drug treatment
group, the inflammatory cell, collagen density, capsule
thickness, and TGF-β levels were significantly reduced;
collagen type 1 and 3 levels were also reduced [90].
Conclusion
This work examined the overall research progress re-
lated to the physical and chemical surface modification
of silicone breast implants to inhibit capsule formation
by fibrosis (Fig. 1, Table 1). We primarily discussed mi-
croscale inflammation and antibiofilm effects. However,
in the future, nanotechnology will lead to further re-
search, and the molecular mechanism of fibrosis, which
has not yet been solved, will be analyzed using molecular
and genetic analyses. These studies are not limited to
silicone implants but have various potential applications,
such as in pacemakers, joint replacements, and esopha-
geal stents, and can provide insights into the biointegra-
tion of medical devices into the human body. Until now,
researchers have found it difficult to translate academic
results to industrial products or have stopped research
in this area. However, further studies that could be prac-
tically applied to the real market should be carried out.
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